STOCK TITAN
  1. Home
  2. Sec-filings
  3. HAO
  4. [6-K] Haoxi Health Technology Ltd Current Report (Foreign Issuer)

Haoxi Health (HAO) replaces Wei, Wei & Co. with new auditor HCL PLLC

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Haoxi Health Technology Limited reported a change in its independent auditor. The audit committee dismissed Wei, Wei & Co., LLP as the company’s independent registered public accounting firm, effective April 3, 2026, and appointed HCL, PLLC as the new independent auditor, also effective April 3, 2026.

The company states that during the fiscal years ended June 30, 2025 and 2024, and the subsequent interim period, the former auditor issued no adverse opinions or qualifications, had no disagreements on accounting or auditing matters, and no “reportable event” occurred. The company also confirms it did not consult HCL, PLLC on accounting or audit issues before the engagement.

Positive

  • None.

Negative

  • None.
Former auditor dismissal effective date April 3, 2026 Effective date of Wei, Wei & Co., LLP dismissal as independent auditor
New auditor appointment date April 3, 2026 Effective date of HCL, PLLC appointment as independent auditor
Fiscal years referenced Years ended June 30, 2025 and 2024 Period assessed for adverse opinions, disagreements, and reportable events
Report month April 2026 Month covered by the Form 6-K report of foreign private issuer
independent registered public accounting firm financial
"to serve as its independent registered public accounting firm, effective on April 3, 2026"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
reportable event regulatory
"there was no “reportable event” within the meaning of Item 16F(a)(1)(v) of Form 20-F"
audit committee financial
"the audit committee (the “Committee”) of the board of directors (the “Board”)"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
Item 16F(a)(1)(v) of Form 20-F regulatory
"no “reportable event” within the meaning of Item 16F(a)(1)(v) of Form 20-F"
Item 304 of Regulation S-K regulatory
"disagreement (as defined in paragraph (a)(1)(iv) of Item 304 of Regulation S-K"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of April 2026

 

Commission File Number: 001-41933

 

Haoxi Health Technology Limited

(Translation of registrant’s name into English)

 

Room 801, Tower C, Floor 8, Building 103

Huizhongli, Chaoyang District

Beijing, China

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒           Form 40-F ☐

 

 

 

 

 

 

Change in Registrant’s Certifying Accountant

 

On April 2, 2026, of the audit committee (the “Committee”) of the board of directors (the “Board”) of Haoxi Health Technology Limited’s (the “Company”), has resolved to dismiss the engagement of Wei, Wei & Co., LLP (the “Former Auditor”) as the Company’s independent registered public accounting firm, effective on April 3, 2026, and to appoint HCL, PLLC (the “New Auditor”) to serve as its independent registered public accounting firm, effective on April 3, 2026.

 

During the two most recent fiscal years ended June 30, 2025 and 2024, and through the subsequent interim period preceding the release, the Former Auditor has neither provided any adverse opinion or qualifications on the Company’s financial statements nor had a disagreement with the Company since their engagement on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements that, if not resolved to the Former Auditor’s satisfaction, would have caused the Former Auditor to make reference to the subject matter thereof in its reports for such fiscal years and interim period.

 

During the two most recent fiscal years ended June 30, 2025 and 2024, and through the subsequent interim period preceding the release, there was no “reportable event” within the meaning of Item 16F(a)(1)(v) of Form 20-F.

 

The Company has provided the Former Auditor with a copy of this report prior to its filing with the U.S. Securities and Exchange Commission (the “SEC”). The Former Auditor has provided a letter to us and addressed to the SEC, which is attached hereto as Exhibit 16.1 and is hereby incorporated herein by reference.

 

During the two most recent fiscal years ended June 30, 2025 and 2024, and any subsequent interim periods prior to the engagement of the New Auditor, neither the Company, nor someone on behalf of the Company, has consulted New Auditor regarding (i) the application of accounting principles to any specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements; (ii) the type of audit opinion that might be rendered on the Company’s financial statements by the New Auditor in either case where written or oral advice provided by the New Auditor would be an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issues; or (iii) any matter that was either the subject of a disagreement (as defined in paragraph (a)(1)(iv) of Item 304 of Regulation S-K and the related instructions thereto) or a reportable event (as described in paragraph (a)(1)(v) of Item 304 of Regulation S-K).

 

1

 

 

EXHIBIT INDEX

 

Number   Description of Exhibit
     
16.1   Letter from Wei, Wei & Co., LLP to the U.S. Securities and Exchange Commission

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Haoxi Health Technology Limited
     
  By: /s/ Zhen Fan
    Zhen Fan
    Chief Executive Officer
     
Date: April 6, 2026    

 

 

3

 

 

Source: View Original Filing on SEC EDGAR

FAQ

What auditor change did Haoxi Health (HAO) disclose?

Haoxi Health dismissed Wei, Wei & Co., LLP and appointed HCL, PLLC as its independent auditor effective April 3, 2026. The change was approved by the audit committee and reported in a Form 6-K as a change in the registrant’s certifying accountant.

Did Wei, Wei & Co., LLP issue adverse opinions on Haoxi Health (HAO)?

No adverse opinions or qualifications were issued by Wei, Wei & Co., LLP on Haoxi Health’s financial statements. The company states that during the fiscal years ended June 30, 2025 and 2024, and the subsequent interim period, there were no such adverse opinions or qualifications.

Were there any disagreements with Haoxi Health’s former auditor?

Haoxi Health reports no disagreements with Wei, Wei & Co., LLP on accounting, disclosure, or audit scope matters. It notes that no unresolved issues required reference in the auditor’s reports for the fiscal years ended June 30, 2025 and 2024 or the related interim period.

Did Haoxi Health consult HCL, PLLC before appointing it as auditor?

The company states it did not consult HCL, PLLC on accounting principles, audit opinions, or reportable issues before engagement. This covers the fiscal years ended June 30, 2025 and 2024, and any subsequent interim periods prior to HCL, PLLC’s appointment.

How did Haoxi Health involve its former auditor in this 6-K filing?

Haoxi Health provided Wei, Wei & Co., LLP a copy of the report before filing and obtained a response letter. The former auditor’s letter, addressed to the SEC, is included as Exhibit 16.1 and incorporated by reference into the report.

Filing Exhibits & Attachments

1 document

Other Documents